TIMOTHY KILKELLY: Open Payments
NPI 1700591732 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,143 in 47 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $1,501 · 2025 $1,143
Food & beverage: $1,143
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 7 | $249 |
| Neurocrine BioSciences, Inc. | 9 | $187 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $158 |
| ABBVIE INC. | 5 | $90 |
| Alkermes, Inc. | 3 | $82 |
| Vanda Pharmaceuticals Inc. | 3 | $82 |
| Almatica Pharma LLC | 3 | $67 |
| Bausch Health US, LLC | 3 | $67 |
| Lundbeck LLC | 2 | $58 |
| E.R. Squibb & Sons, L.L.C. | 1 | $32 |
Products named: Auvelity, INGREZZA, CAPLYTA, VRAYLAR, ARISTADA, FANAPT, REXULTI, LOREEV XR.
Industry payments across PA — which companies pay providers there.
